Messenger RNA delivery of a cartilage-anabolic transcription factor as a disease-modifying strategy for osteoarthritis treatment

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Aini, Hailati ^a   Itaka, Keiji ^b   Fujisawa, Ayano ^a   Uchida, Hirokuni ^b   Uchida, Satoshi ^b   Fukushima, Shigeto ^a   Kataoka, Kazunori ^a,b   Saito, Taku ^b   Chung, Ung Il ^a,b   Ohba, Shinsuke ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICELLE; NANOCOMPOSITE; TRANSCRIPTION FACTOR;

ANIMAL; ARTICULAR CARTILAGE; CHEMISTRY; DISEASE MODEL; GENE EXPRESSION; GENE TRANSFER; GENETICS; INTRAARTICULAR DRUG ADMINISTRATION; METABOLISM; MICELLE; MOUSE; OSTEOARTHRITIS; OSTEOARTHRITIS, KNEE; PATHOLOGY; REPORTER GENE;

ANIMALS; CARTILAGE, ARTICULAR; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENES, REPORTER; INJECTIONS, INTRA-ARTICULAR; MICE; MICELLES; NANOCOMPOSITES; OSTEOARTHRITIS; OSTEOARTHRITIS, KNEE; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 84953276749     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18743     Document Type: Article

References (54)

1. Hawker, G. A. & Stanaitis, I. Osteoarthritis year in review 2014: clinical. Osteoarthritis Cartilage 22, 1953-1957 (2014).
2. Felson, D. T. et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann. Intern. Med. 133, 635-646 (2000).
3. Cross, M. et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann. Rheum. Dis. 73, 1323-1330 (2014).
4. Arden, N. & Nevitt, M. C. Osteoarthritis: epidemiology. Best Pract. Res. Clin. Rheumatol. 20, 3-25 (2006).
5. Reginster, J. Y. & Khaltaev, N. G. Introduction and WHO perspective on the global burden of musculoskeletal conditions. Rheumatology (Oxford) 41 Supp 1, 1-2 (2002).
6. Centers for Disease, C. & Prevention. Prevalence of disabilities and associated health conditions among adults-United States, 1999. MMWR. Morb. Mortal. Wkly. Rep. 50, 120-125 (2001).
7. Hunter, D. J. Pharmacologic therapy for osteoarthritis - the era of disease modification. Nat. Rev. Rheum. 7, 13-22 (2011).
8. Jotanovic, Z., Mihelic, R., Sestan, B. & Dembic, Z. Emerging pathways and promising agents with possible disease modifying effect in osteoarthritis treatment. Curr. Drug Targets 15, 635-661 (2014).
9. Tsezou, A. Osteoarthritis year in review 2014: genetics and genomics. Osteoarthritis Cartilage 22, 2017-2024 (2014).
10. Putnam, D. Polymers for gene delivery across length scales. Nat. Mater. 5, 439-451 (2006).
11. Sahin, U., Kariko, K. & Tureci, O. mRNA-based therapeutics - developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759-780 (2014).
12. Kormann, M. S. et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat. Biotechnol. 29, 154-157 (2011).
13. Warren, L. et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7, 618-630 (2010).
14. Plews, J. R. et al. Activation of pluripotency genes in human fibroblast cells by a novel mRNA based approach. PLoS One 5, e14397 (2010).
15. Tavernier, G. et al. Activation of pluripotency-associated genes in mouse embryonic fibroblasts by non-viral transfection with in vitro-derived mRNAs encoding Oct4, Sox2, Klf4 and cMyc. Biomaterials 33, 412-417 (2012).
16. Uchida, S. et al. In vivo messenger RNA introduction into the central nervous system using polyplex nanomicelle. PLoS One 8, e56220 (2013).
17. Baba, M., Itaka, K., Kondo, K., Yamasoba, T. & Kataoka, K. Treatment of neurological disorders by introducing mRNA in vivo using polyplex nanomicelles. J. Control Release 201, 41-48 (2015).
18. Uchida, H. et al. Odd-even effect of repeating aminoethylene units in the side chain of N-substituted polyaspartamides on gene transfection profiles. J. Am. Chem. Soc. 133, 15524-15532 (2011).
19. Uchida, H. et al. Modulated protonation of side chain aminoethylene repeats in N-substituted polyaspartamides promotes mRNA transfection. J. Am. Chem. Soc. 136, 12396-12405 (2014).
20. Kimura, A. et al. Runx1 and Runx2 cooperate during sternal morphogenesis. Development 137, 1159-1167 (2010).
21. LeBlanc, K. T. et al. Runx1 Activities in Superficial Zone Chondrocytes, Osteoarthritic Chondrocyte Clones and Response to Mechanical Loading. J. Cell. Physiol. 230, 440-448 (2014).
22. Yano, F. et al. A novel disease-modifying osteoarthritis drug candidate targeting Runx1. Ann. Rheum. Dis. 72, 748-753 (2013).
23. Johnson, K. et al. A stem cell-based approach to cartilage repair. Science 336, 717-721 (2012).
24. Kamekura, S. et al. Osteoarthritis development in novel experimental mouse models induced by knee joint instability. Osteoarthritis Cartilage 13, 632-641 (2005).
25. Glasson, S. S., Chambers, M. G., Van Den Berg, W. B. & Little, C. B. The OARSI histopathology initiative-recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthritis Cartilage 18 Suppl 3, S17-23 (2010).
26. Bi, W., Deng, J. M., Zhang, Z., Behringer, R. R. & de Crombrugghe, B. Sox9 is required for cartilage formation. Nat. Genet. 22, 85-89 (1999).
27. Akiyama, H., Chaboissier, M. C., Martin, J. F., Schedl, A. & de Crombrugghe, B. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev. 16, 2813-2828 (2002).
28. Bell, D. M. et al. SOX9 directly regulates the type-II collagen gene. Nat. Genet. 16, 174-178 (1997).
29. Lefebvre, V., Huang, W., Harley, V. R., Goodfellow, P. N. & de Crombrugghe, B. SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene. Mol. Cell. Biol. 17, 2336-2346 (1997).
30. Kapoor, M., Martel-Pelletier, J., Lajeunesse, D., Pelletier, J. P. & Fahmi, H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheum. 7, 33-42 (2011).
31. Daheshia, M. & Yao, J. Q. The interleukin 1beta pathway in the pathogenesis of osteoarthritis. J. Rheumatol. 35, 2306-2312 (2008).
32. Kim, H. A., Lee, Y. J., Seong, S. C., Choe, K. W. & Song, Y. W. Apoptotic chondrocyte death in human osteoarthritis. J. Rheumatol. 27, 455-462 (2000).
33. Kuhn, K., D'Lima, D. D., Hashimoto, S. & Lotz, M. Cell death in cartilage. Osteoarthritis Cartilage 12, 1-16 (2004).
34. Nel, A., Xia, T., Madler, L. & Li, N. Toxic potential of materials at the nanolevel. Science 311, 622-627 (2006).
35. Medina, C., Santos-Martinez, M. J., Radomski, A., Corrigan, O. I. & Radomski, M. W. Nanoparticles: pharmacological and toxicological significance. Br. J. Pharmacol. 150, 552-558 (2007).
36. Evans, C. H., Gouze, J. N., Gouze, E., Robbins, P. D. & Ghivizzani, S. C. Osteoarthritis gene therapy. Gene Ther. 11, 379-389 (2004).
37. Evans, C. H. & Huard, J. Gene therapy approaches to regenerating the musculoskeletal system. Nat. Rev. Rheum. 11, 234-242 (2015).
38. Goodrich, L. R. et al. scAAVIL-1ra dosing trial in a large animal model and validation of long-term expression with repeat administration for osteoarthritis therapy. Gene Ther. 22, 536-545 (2015).
39. Subramanian, A., Ranganathan, P. & Diamond, S. L. Nuclear targeting peptide scaffolds for lipofection of nondividing mammalian cells. Nat. Biotechnol. 17, 873-877 (1999).
40. Tavernier, G. et al. mRNA as gene therapeutic: how to control protein expression. J. Control Release 150, 238-247 (2011).
41. Nomoto, T. et al. In situ quantitative monitoring of polyplexes and polyplex micelles in the blood circulation using intravital real-time confocal laser scanning microscopy. J. Control Release 151 (2011).
42. Kamata, H., Akagi, Y., Kayasuga-Kariya, Y., Chung, U. I. & Sakai, T. "Nonswellable" hydrogel without mechanical hysteresis. Science 343, 873-875 (2014).
43. Wang, Y. et al. Runx1/AML1/Cbfa2 mediates onset of mesenchymal cell differentiation toward chondrogenesis. J. Bone Miner. Res. 20, 1624-1636 (2005).
44. Smith, N. et al. Overlapping expression of Runx1(Cbfa2) and Runx2(Cbfa1) transcription factors supports cooperative induction of skeletal development. J. Cell. Physiol. 203, 133-143 (2005).
45. Huang, G. et al. Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J. 20, 723-733 (2001).
46. Zhang, L., Lukasik, S. M., Speck, N. A. & Bushweller, J. H. Structural and functional characterization of Runx1, CBF beta, and CBF beta-SMMHC. Blood Cells. Mol. Dis. 30, 147-156 (2003).
47. Ruan, M. Z. et al. Proteoglycan 4 expression protects against the development of osteoarthritis. Sci. Transl. Med. 5, 176ra134 (2013).
48. Ogawa, H., Kozhemyakina, E., Hung, H. H., Grodzinsky, A. J. & Lassar, A. B. Mechanical motion promotes expression of Prg4 in articular cartilage via multiple CREB-dependent, fluid flow shear stress-induced signaling pathways. Genes Dev. 28, 127-139 (2014).
49. Kozhemyakina, E. et al. Identification of a Prg4-expressing articular cartilage progenitor cell population in mice. Arthritis Rheumatol. 67, 1261-1273 (2015).
50. Tokuhiro, S. et al. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat. Genet. 35, 341-348 (2003).
51. Yamada, R., Tokuhiro, S., Chang, X. & Yamamoto, K. SLC22A4 and RUNX1: identification of RA susceptible genes. J. Mol. Med. (Berl) 82, 558-564 (2004).
52. Kay, J. & Calabrese, L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 43 Suppl 3, iii2-iii9 (2004).
53. Kanayama, N. et al. A PEG-based biocompatible block catiomer with high buffering capacity for the construction of polyplex micelles showing efficient gene transfer toward primary cells. Chem.Med.Chem. 1, 439-444 (2006).
54. Ailixiding, M. et al. Pivotal role of Sirt6 in the crosstalk among ageing, metabolic syndrome and osteoarthritis. Biochem. Biophys. Res. Commun. 466, 319-326 (2015).